Tracleer (Bosentan) Receives New Indication In Patients With Systemic Sclerosis And Active Digital Ulcer Disease
Actelion Pharmaceuticals UK Ltd announced that Tracleer® (bosentan), a dual endothelin receptor antagonist, has been approved in the UK and Ireland for the reduction of the number of new digital ulcers (DUs) in patients with systemic sclerosis (SSc) and ongoing DU disease.1DUs are a frequent, extremely painful and disabling complication of SSc2, caused by a reduced blood flow to the fingers and toes.
This post is an original post by ScienceDaily: Skin Care News
Posted: April 29th, 2008 under skin health.
Comments: none
Write a comment